Fulgent Genetics, Inc.
FLGTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeFulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company carries a $542.9M market cap, placing it firmly in the small-cap category. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Market Cap
$542.9M
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-14.30
EPS (TTM)
$-2.83
EPS (Fwd)
$-1.38
ROE
-8.1%
ROA
-6.3%
Cash
$257.0M
Total Debt
$9.6M
Free CF
-$90.9M
52W Change
-11.6%
Annual Financials
Cash vs Debt
Where FLGT stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, FLGT finished 5.57% above its 150-day moving average ($18.85) and 5.46% below its 200-day moving average ($21.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FLGT overbought or oversold?
At the August 24, 2026 close, FLGT's RSI(14) was 80.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Fulgent Genetics, Inc. holds $257.0M in cash against $9.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$90.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -8.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $619.0M (2022) to $322.7M (2025), a 48% decline worth watching.
With cash comfortably exceeding debt, FLGT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fulgent Genetics, Inc. and its sector.